tiprankstipranks
Advertisement
Advertisement

ACXP Stock Latest News

Acurx Pharmaceuticals Charts Risky but Promising CDI Path
Company AnnouncementsAcurx Pharmaceuticals Charts Risky but Promising CDI Path
3d ago
ACXP
Acurx reports Q1 EPS (62c) vs. ($2.15) last year
PremiumThe Fly
Acurx reports Q1 EPS (62c) vs. ($2.15) last year
4d ago
ACXP
Acurx files to sell 1.65M shares of common stock for holders
PremiumThe Fly
Acurx files to sell 1.65M shares of common stock for holders
11d ago
ACXP
Acurx files to sell 1.3M shares of common stock for holders
PremiumThe Fly
Acurx files to sell 1.3M shares of common stock for holders
11d ago
ACXP
Acurx announces $7.1M registered direct offering priced at-the-market
PremiumThe Fly
Acurx announces $7.1M registered direct offering priced at-the-market
30d ago
ACXP
Acurx Pharmaceuticals Secures New Financing to Advance Pipeline
PremiumCompany AnnouncementsAcurx Pharmaceuticals Secures New Financing to Advance Pipeline
30d ago
8K
ACXP
New to The Street announce re-signing of Acurx Pharmaceuticals
Premium
The Fly
New to The Street announce re-signing of Acurx Pharmaceuticals
1M ago
ACXP
Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
Premium
The Fly
Acurx: KIPO grantes new patent covering DNA Polymerase IIIC inhibitors
2M ago
ACXP
Acurx price target lowered to $10 from $20 at Alliance Global
PremiumThe Fly
Acurx price target lowered to $10 from $20 at Alliance Global
2M ago
ACXP
Acurx reports Q4 EPS (73c) vs. ($3.29) last year
PremiumThe Fly
Acurx reports Q4 EPS (73c) vs. ($3.29) last year
2M ago
ACXP
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
PremiumMarket News
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate
2M ago
ACXP
ACXP Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ACXP Earnings this Week: How Will it Perform?
2M ago
ACXP
Acurx Advances Ibezapolstat Program for Recurrent C. difficile
PremiumCompany AnnouncementsAcurx Advances Ibezapolstat Program for Recurrent C. difficile
2M ago
8K
ACXP
Acurx announces new ibezapolstat clinical trial program
Premium
The Fly
Acurx announces new ibezapolstat clinical trial program
2M ago
ACXP
Acurx files to sell 750,000 shares of common stock for holders
Premium
The Fly
Acurx files to sell 750,000 shares of common stock for holders
3M ago
ACXP
Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO
PremiumThe Fly
Acurx awarded patent covering DNA Polymerase IIIC inhibitors by USPTO
3M ago
ACXP
One new option listing and option delistings on January 20th
PremiumThe Fly
One new option listing and option delistings on January 20th
4M ago
CVM
TEF
Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation
PremiumRatings
Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation
6M ago
ACXP
Acurx Pharmaceuticals Reports Q3 2025 Financial Results
PremiumCompany Announcements
Acurx Pharmaceuticals Reports Q3 2025 Financial Results
6M ago
ACXP
Acurx Pharmaceuticals’ Earnings Call: Achievements Amid Challenges
PremiumCompany AnnouncementsAcurx Pharmaceuticals’ Earnings Call: Achievements Amid Challenges
6M ago
ACXP
Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
Premium
Ratings
Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
6M ago
ACXP
Acurx reports Q3 EPS ($1.23) vs. ($3.45) last year
Premium
The Fly
Acurx reports Q3 EPS ($1.23) vs. ($3.45) last year
6M ago
ACXP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >